Medpace (MEDP) Q2 2025 Earnings Call July 22, 2025 09:00 AM ET Speaker0Good day ladies and gentlemen and welcome to the Medpace Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' remarks, there will be a question and answer session. If you'd like to ask a question, please press 11 on your phone. If your question has been answered and you'd like to remove yourself from the queue, simply press 11 again.As a reminder, this c ...

ab 18 July 2025 Global Research China Healthcare China preclinical CRO expert call takeaways H125: slight price & volume recovery; tipping point may not occur until 2026 On 18 July, we invited a senior executive from a domestic medium-sized preclinical CRO firm to share his views. He noted a slight recovery in China's preclinical CRO industry. Overall order inflow has increased modestly YoY for both volume (up <10%) and price (up 5-10%) YTD, with profits staying low. In his view, pharmaceutical R&D is gener ...

LOS ANGELES, July 18, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fortrea Holdings Inc. ("Fortrea" or the "Company") (NASDAQ: FTRE) investors of a class action representing investors that bought securities between July 3, 2023 and February 28, 2025, inclusive (the "Class Period"). Fortrea investors have until August 1, 2025 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal r ...

The market expects Medpace (MEDP) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Ju ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fortrea Holdings Inc. regarding a class action lawsuit due to alleged misleading statements and overestimations related to the company's financial projections and business model [1][3]. Summary by Sections Class Action Details - The class period for the lawsuit is from July 3, 2023, to February 28, 2025 [3]. - Allegations include that Fortrea overestimated revenue contributions from long-term projects, overstated cost savings from exiting transition services agreements, and inflated EBITDA targets for 2025 [3]. Allegations Breakdown - Fortrea allegedly overestimated the revenue from its Pre-Spin Projects for 2025 [3]. - The company is accused of overstating potential cost savings from exiting certain agreements [3]. - As a result, the company's previously announced EBITDA targets for 2025 were inflated [3]. - The viability of Fortrea's post-spin-off business model and its financial prospects were also allegedly overstated [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 1, 2025, to participate in potential recovery [4]. - Registered shareholders will receive updates through a portfolio monitoring software [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/psl ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=154294&from=3 CLASS PERIOD: Ju ...

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=153678&from=3 CLASS PERIOD: Ju ...

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea is a global clinical research organization (CRO) that provides development solutions for biopharmaceutical products and medical devices [2]. - The company was spun off from Labcorp in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit claims that Fortrea overestimated revenue contributions from pre-spin projects, overstated cost savings from exiting transition services agreements (TSAs), and inflated its EBITDA targets for 2025 [3]. - Specific allegations include: - Overestimation of revenue from pre-spin projects [3]. - Overstatement of cost savings from exiting TSAs [3]. - Inflated EBITDA targets for 2025 [3]. - Overstated viability of Fortrea's post-spin business model [3]. Impact of Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a lack of material cost savings from exiting TSAs, leading to a stock price drop of over 12% [4]. - On December 6, 2024, Baird Equity Research downgraded Fortrea to neutral, resulting in an 8% decline in stock price after the company canceled two scheduled conferences [5]. Financial Performance Disclosure - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, revealing that pre-spin projects were underperforming and negatively impacting financial performance [6]. - Following this announcement, Fortrea's stock price fell by more than 25% [6].

Core Viewpoint - Fortrea Holdings Inc. is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives made misleading statements regarding its financial performance and business model following its spin-off from Labcorp Holdings Inc. [1][3] Company Overview - Fortrea Holdings Inc. is a global clinical research organization (CRO) that provides biopharmaceutical product and medical device development solutions to various customers [2]. - The company was spun off from Labcorp Holdings Inc. in June 2023, with ongoing long-term projects at the time of the spin-off [2]. Allegations of the Lawsuit - The lawsuit alleges that Fortrea overestimated revenue contributions from pre-spin projects, overstated cost savings from exiting transition services agreements (TSAs), and inflated its EBITDA targets for 2025 [3]. - Specific claims include that Fortrea's business model viability and financial prospects were overstated, leading to significant stock price declines following negative reports from analysts [3][4][5]. Stock Performance and Analyst Reports - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model, resulting in a stock price drop of over 12% [4]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral from outperform on December 6, 2024, leading to an additional stock price decline of over 8% [5]. - On March 3, 2025, Fortrea announced that its revenue and adjusted EBITDA projections for 2025 were not aligned with prior expectations, causing a stock price drop of more than 25% [6]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Fortrea securities during the class period to seek appointment as lead plaintiff in the lawsuit [7]. - The lead plaintiff represents the interests of all class members and can select a law firm for litigation [8].